Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31488806 | 1.00 | TGFBR1 (0.48) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL4082387 | 1.00 | TGFBR1 (0.48) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL29819412 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL455811 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL29385234 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL31651029 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL19283433 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL19283432 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL1229828 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 | |
| SCHEMBL1229824 | 0.98 | TGFBR1 (0.47) | TGFBR1MMETERTCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| US-5750555-A | NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | claimed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | claimed |
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | disclosed |
| US-9751911-B2 | Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-05 | — | — | US | disclosed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | disclosed |
| US-5750555-A | NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | TGFBR1 3020/4885MME 1788/4885TERT 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.